Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€8.78

€8.78

2.260%
0.19
2.260%
-
 
27.03.24 / Tradegate WKN: A1JTC2 / Name: Adocia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Adocia Stock

There is an upward development for Adocia compared to yesterday, with an increase of €0.19 (2.260%).
Our community identified positive and negative aspects for Adocia stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Adocia stock. On the other hand our users think that "EBIT growth" could be a problem in the future.

Pros and Cons of Adocia in the next few years

Pros
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Adocia vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Adocia 2.260% -8.921% -10.041% 217.541% -25.340% -13.069% -37.286%
Valneva SE 1.430% 6.985% 13.651% -21.919% -23.883% -65.029% 5.370%
Nanobiotix -0.540% -2.116% -7.191% 75.633% -13.551% -57.955% -48.516%
Transgene S.A. -0.550% -3.220% 6.287% -41.514% -19.254% -57.981% -60.939%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-25

Diving into the financials of a company, such as Adocia from the Biotechnology & Medical Research industry, is akin to peering through a microscope for an in-depth examination of its fiscal health and market position. On a preliminary scan, the squad of numbers and ratios might seem daunting, but they hold the secrets to understanding the company's underlying story.

Starting off, one of the most striking observations in Adocia's financial statements is a consistently negative net income over the last three fiscal years. The trend is often an orange flag, signaling the potential for trouble on the horizon. The negative total stockholder equity further points towards a company that has, historically, been spending more than it's earning.

*The Pros: *

Comments

Buy Adocia
Show more

Sell Adocia
Show more

Sell Adocia
Show more